CB-86

CB-86
Identifiers
	IUPAC name N-cyclopropyl-8-[3-hydroxy-5-(2-methyloctan-2-yl)phenoxy]octanamide;
CAS Number	1150586-64-3;
PubChem CID	42625202;
ChemSpider	24705451;
ChEMBL	ChEMBL490648;
Chemical and physical data
Formula	C26H43NO3
Molar mass	417.634 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCCCCCC(C)(C)C1=CC(=CC(=C1)OCCCCCCCC(=O)NC2CC2)O;
	InChI InChI=1S/C26H43NO3/c1-4-5-6-11-16-26(2,3)21-18-23(28)20-24(19-21)30-17-12-9-7-8-10-13-25(29)27-22-14-15-22/h18-20,22,28H,4-17H2,1-3H3,(H,27,29); Key:PVAOGZXUOOHSMN-UHFFFAOYSA-N;

CB-86 is a synthetic cannabinoid drug which was developed as a hybrid between classical/nonclassical cannabinoids such as THC and CP 47,497 with endogenous cannabinoid ligands such as anandamide. It acts as a partial agonist at CB1 receptors with a K_i of 5.6 nM, and an antagonist of CB2 receptors with a K_i of 7.9 nM. It has analgesic effects in studies on mice.^[1]

References

^ Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, et al. (April 2009). "New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo". Journal of Medicinal Chemistry. 52 (8): 2506–2514. doi:10.1021/jm8016255. PMID 19331413.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[Brizzi_2009-1] Brizzi A, Brizzi V, Cascio MG, Corelli F, Guida F, Ligresti A, et al. (April 2009). "New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo". Journal of Medicinal Chemistry. 52 (8): 2506–2514. doi:10.1021/jm8016255. PMID 19331413.

[1]

See also

References